SCHEMBL6329185

SCHEMBL6329185

CC/C(Nc1ccc(C(=O)O)cc1)=C1/C(=O)Nc2cc(OC)c(OC)cc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 4/20 0.48
PKM P14618 1/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
NR1H4 Q96RI1 1/20 0.40
F11 P03951 3/20 0.40
EGFR P00533 1/20 0.39
TSHR P16473 1/20 0.39
GAA P10253 2/20 0.39
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 1/20 0.38
KLKB1 P03952 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
CA7 P43166 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6329194 1.00 RET (0.48) RETPKMMEN1KMT2APOLB
SCHEMBL6331585 0.90 RET (0.45) RETMEN1KMT2APOLBEGFR
SCHEMBL6331591 0.90 RET (0.45) RETMEN1KMT2APOLBEGFR
SCHEMBL7472909 0.89 RET (0.47) RETMEN1KMT2AEGFRALDH1A1
SCHEMBL6331141 0.89 RET (0.47) RETMEN1KMT2AEGFRALDH1A1
SCHEMBL6331148 0.89 RET (0.47) RETMEN1KMT2AEGFRALDH1A1
SCHEMBL6333341 0.89 RET (0.54) RETEGFRALDH1A1
SCHEMBL6333335 0.89 RET (0.54) RETEGFRALDH1A1
SCHEMBL6336096 0.89 MAPT (0.54) RETMEN1KMT2APOLBTSHR
SCHEMBL6328903 0.89 RET (0.44) RETMEN1KMT2AEGFRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-01-13 US disclosed
US-6794395-B1 Substituted indolinones, their manufacture and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-09-21 US disclosed
EP-1212318-A1 SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS Boehringer Ingelheim Pharma KG (DE) 2002-06-12 EP disclosed
WO-2001016130-A1 SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments CCNE1, CDK1, CCNI RET 154/4885PKM 915/4885MEN1 1645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.